- completedNot Applicable
A prospective study to assess the impact and benefits of an artificial intelligence system in double reading for breast cancer screening
This UK study tests whether an artificial intelligence (AI) computer programme called Mia can help doctors read routine breast screening X-rays. Half of the women taking part will have their mammograms checked by two specialists plus the AI. The goal is to see if AI helps spot cancer earlier.
United Kingdom · England - recruiting
Optimal personalised treatment of early breast cancer using multiparameter analysis
This study looks at whether a specialised tumour test can help women with early breast cancer safely avoid chemotherapy. Researchers want to see if hormone therapy alone works just as well for some women, sparing them difficult side effects without increasing the risk of their cancer returning.
United Kingdom · England · Australia - completedPhase III
A randomized trial of armpit (axilla) treatment for women with early stage breast cancer. POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy.
The POSNOC trial looks at the best way to treat the armpit in women with early breast cancer. If cancer is found in one or two armpit glands, researchers want to see if standard drug therapies alone work just as well as having extra armpit surgery or radiotherapy.
United Kingdom · England · Australia - authorisedTherapeutic confirmatory (Phase III)
PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin
This study looks at whether women having breast cancer surgery really need antibiotics to prevent wound infections. Researchers are comparing a standard antibiotic called cefazolin with a harmless salt-water dummy drip (placebo) to see if skipping antibiotics is safe, helping to reduce unnecessary medication use and potential side effects.
France - authorisedTherapeutic confirmatory (Phase III)
Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan
This study looks at whether taking a common steroid tablet called dexamethasone can protect the lungs of people with breast cancer. It tests if the steroid helps prevent lung inflammation in patients receiving an effective cancer medicine called trastuzumab deruxtecan (T-DXd) over a 12-month period.
Italy - authorisedTherapeutic exploratory (Phase II)
Optimization of De-EscalatiON strategies in early breast cancer
This study looks at treating early-stage breast cancer with gentler, more personalised care. Researchers want to see if reducing the amount or intensity of chemotherapy and other drugs works just as well to clear cancer while sparing people from harsh, unwanted side effects.
Italy - authorisedPhase I and Phase II (Integrated)- Other
Neoadjuvant trastuzumab, pertuzumab and zongertinib without chemotherapy in HER2-positive breast cancer: the TRAIN-5 study
This clinical trial tests a new treatment combination for adults with HER2-positive breast cancer before surgery. Researchers are investigating whether adding a new targeted tablet called zongertinib to standard targeted medicines allows patients to avoid chemotherapy, while checking how safe the treatment is and how well it shrinks tumours.
Netherlands - recruitingTherapeutic confirmatory (Phase III)
SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients
The SERAFA-1 study looks at a new drug combination for people with advanced ER-positive, HER2-negative breast cancer. It tests whether taking camizestrant together with ribociclib as a first treatment helps control the cancer for longer and delays the need for other cancer therapies.
Poland · Spain · France - authorisedTherapeutic exploratory (Phase II)
Anti-HER2 treatment Discontinuation Guided by ctDNA in Patients with HER2-Positive Metastatic Breast Cancer with Sustained Disease Control: PHENIX Trial
This study looks at people with advanced HER2-positive breast cancer whose disease is stable. Researchers want to see if regular blood tests can safely tell them when it is okay to pause targeted drugs like Perjeta or Phesgo, and if restarting them later works well if cancer signs return.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors
This study is testing a new medicine, ABBV-155, by itself and with other cancer drugs called taxanes. It's for adults with certain cancers like lung or breast cancer that have come back or not responded to previous treatments.
Netherlands - recruitingTherapeutic confirmatory (Phase III)
A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL
This study is looking at a new treatment called Bavencio for a specific type of breast cancer (triple negative). It's a large study to see if adding Bavencio after initial treatment can help people live longer without their cancer coming back.
Italy - recruitingTherapeutic use (Phase IV)
FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial
This study looks at a new test, RECAP, to see if it can predict how well a breast cancer treatment called Talzenna (talazoparib) will work. It focuses on people with advanced breast cancer to find out if the treatment can keep the cancer from growing for at least four months.
Netherlands - recruitingTherapeutic use (Phase IV)
Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement in breast cancer.
This study looks at how a special MRI scan, using a dye called Elucirem, helps doctors see breast cancer. We're checking if what the MRI shows matches what doctors find when they examine breast tissue closely, to better understand and treat the disease.
Spain - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
United States · Australia · Belgium - recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study is looking at a new combination of medicines for a certain type of advanced breast cancer. It compares a new drug, inavolisib, with existing treatments to see if it's more effective and safe for people whose cancer has a specific genetic change (PIK3CA mutation).
United States · Argentina · Australia - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
United States · Argentina · Belgium - active not recruitingPHASE3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This study looks at new drug combinations for advanced breast cancer that has grown despite previous treatments. It compares different medications, including gedatolisib, fulvestrant, and palbociclib, to see if they are safe and effective.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
United States · Australia · Austria - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This study is looking at new combinations of medicines for advanced lung or breast cancer. We want to see if they are safe, how much medicine gets into the body, and if they show early signs of working. It's for adults with certain types of advanced cancer.
United States · Australia · Canada - active not recruitingPHASE3
PALbociclib CoLlaborative Adjuvant Study
This study is looking at whether adding a drug called palbociclib to standard hormone therapy can improve outcomes for people with some types of early breast cancer. It's a large, international study involving many patients.
United States · Australia · Austria - recruitingPHASE3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
This study looks at new drug combinations for advanced breast cancer. It compares a new treatment (gedatolisib with other drugs) to standard treatments. The aim is to find better ways to treat hormone-positive, HER2-negative breast cancer that has spread.
United States · Argentina · Australia - active not recruitingPHASE3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.
United States · Argentina · Australia - active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
United States · Australia · Austria - active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
United States · Argentina · Australia - recruitingPHASE3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
This study is testing a new medicine, PF-07248144, with an existing one, fulvestrant, for advanced breast cancer that has grown despite previous treatment. It aims to see if this combination is safe and effective.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
United States · Belgium · Brazil - recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
This study looks at two drug combinations, inavolisib with fulvestrant, and alpelisib with fulvestrant, for advanced breast cancer that has specific genetic changes and has already been treated with certain therapies. It aims to see which combination works better and is safer.
United States · Argentina · Australia - active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
United States · Australia · Austria - active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This study is testing a new medicine called AZD8205, by itself or with other cancer drugs. It's for people with advanced cancers like breast, ovarian, or lung cancer, to see if it's safe and helps shrink tumours.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
This study is for people with advanced breast cancer that has grown despite previous treatments. It tests a new combination of targeted radiation therapy and chemotherapy to see if it can stop cancer growth and if it's safe. We're looking at different doses to find the best way to use these treatments.
United States · Australia · Canada - recruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
United States · Argentina · Australia - active not recruiting
Male Breast Cancer: Understanding the Biology for Improved Patient Care
This study looks at breast cancer in men. Researchers are gathering information and samples from men with breast cancer to better understand the disease and improve how it's treated. It's a large international effort to learn more about this rare condition.
United States · Belgium · Brazil - active not recruitingPHASE3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.
United States · Argentina · Australia - recruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
United States · Argentina · Australia - active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
United States · Argentina · Belgium - completed
A study for women who have small breast cancers found by screening, comparing removal of the cancer by standard surgery with a smaller procedure, which is more like a biopsy
This study looks at a gentler, needle-based procedure to remove very small breast cancers found through routine screening. Researchers want to see if this simple procedure, called vacuum-assisted excision, works just as well as standard surgery while causing less scarring, less discomfort, and a quicker recovery.
United Kingdom · England · Northern Ireland - completed
PRE-DX – the impact of earlier genomic testing in the treatment of breast cancer
This UK study looks at whether doing a routine tumour test earlier can improve breast cancer care. Doctors usually test tissue removed during surgery to decide if chemotherapy is needed. This study tests tissue taken at the first biopsy instead, aiming to speed up treatment decisions and reduce patient waiting times.
United Kingdom · England · Scotland - completedPhase I/II
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with CDK4/6 inhibitor
This clinical trial is testing a new targeted radiation treatment called Lutetium-NeoB alongside a standard chemotherapy tablet, capecitabine. It is for adults with advanced, hormone-positive breast cancer that has grown after previous hormone therapies. Researchers want to find the safest dose and see how well it works against the cancer.
United Kingdom · England · Australia - completed
SUPREMO, an MRC Phase III randomised trial to assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy
The SUPREMO study looks at whether radiotherapy to the chest wall helps women with intermediate-risk breast cancer after a mastectomy. Researchers want to find out if this treatment stops the cancer from returning, or if it can be safely avoided to spare patients from unnecessary side effects.
United Kingdom · Scotland · Australia - recruitingNot Applicable
Study to assess if sweat analysis from human finger tips can confirm breast cancer diagnosis
Researchers in South Yorkshire are testing whether sweat from your fingertips can help detect breast cancer. This simple, painless study checks if chemical patterns in sweat can spot cancer accurately, potentially offering a quick, comfortable alternative or addition to mammograms and biopsies in the NHS.
United Kingdom · England - completed
Breast activity and healthy eating after diagnosis 3
This UK clinical study looks at whether a healthy eating and strength-training plan can help women having chemotherapy for advanced breast cancer. Researchers want to see if keeping muscle and losing excess body fat reduces treatment side effects, improves quality of life, and helps chemotherapy work as well as possible.
United Kingdom · England - completed
A feasibility study of offering breast cancer risk assessment to women through general practice
This UK study is looking at whether GP surgeries can help women find out their breast cancer risk. Women aged 40 to 49 complete an online health tool and can choose to give a saliva sample. This helps doctors see who might benefit from extra checks or lifestyle advice.
United Kingdom · England - completedPhase II
Safety of AZD4547 in breast cancer patients
This study tests a new medicine called AZD4547 for women with oestrogen receptor-positive breast cancer. It looks at whether adding AZD4547 to usual hormone treatments (anastrozole or letrozole) works better and is safe compared to switching to another standard hormone treatment called exemestane when previous treatment has stopped working.
United Kingdom · England · Scotland - recruiting
Evaluating the uptake and impact of an adapted breast cancer risk assessment pathway in primary care amongst South Asian and Black women
Breast cancer is common, but many women do not know their personal risk. The PREVENT-Breast study tests whether offering an online risk check through GP surgeries works well for Black and South Asian women aged 40 to 49. It aims to help women understand and manage their health.
United Kingdom · England - completedPhase III
Response to optimal selection of neo-adjuvant chemotherapy in operable breast cancer
This UK clinical trial looks at breast cancer treatment given before surgery. It aims to find out whether two special tests can help doctors pick the best chemotherapy drugs for each person, shrinking the tumour more effectively and improving care.
United Kingdom · England - completed
Can patients with residual cancer after chemotherapy for early breast cancer be identified with multiple ultrasound-guided biopsies?
This study looks at whether ultrasound-guided needle biopsies can reliably check for remaining breast cancer after chemotherapy. For some people, chemotherapy clears the cancer completely. Researchers want to see if precise biopsies can confirm this, which could help doctors discover if surgery might safely be avoided in the future.
United Kingdom · England · Northern Ireland - completedNot Applicable
A study to help understand the outcomes of pre-surgical treatment for breast cancer
This UK study looks at how breast cancer treatments given before surgery—such as chemotherapy or hormone therapy—are used across the NHS. Researchers want to see how well these treatments shrink tumours and how doctors decide on surgery afterwards. It simply collects routine medical information without changing normal care.
United Kingdom · England · Northern Ireland